NCT03712943View on ClinicalTrials.gov

Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

October 23, 2018

Primary Completion Date

September 1, 2021

Study Completion Date

January 18, 2024

Conditions
Colorectal CancerMetastatic Colorectal CancerColon Cancer
Interventions
DRUG

Regorafenib

Regorafenib orally 80 mg daily for 21 days (3 weeks on, 1 week off).

DRUG

Nivolumab

Nivolumab 240 mg administered intravenously every 2 weeks.

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER